Immedica Pharma US Inc.
Chicago, IL Doing business as Marinus Pharmaceuticals
- UEI
- MS6UM2NBDW91
- CAGE
- 4BX80
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 400 N Aberdeen St #959, Chicago, IL 60642, USA
- Website
- marinuspharma.com
- Founded
- 2003
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of intravenous drug ganaxolone | Office of the Assistant Secretary for Preparedness and Response | $33,656,933 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Biogen U.s. Corporation | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Mirum Pharmaceuticals, Inc. | San Mateo, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Lundbeck LLC | Deerfield, IL | 325412 Pharmaceutical Preparation Manufacturing |
| UCB Pharma, Inc. | Smyrna, GA | 325412 Pharmaceutical Preparation Manufacturing |
| Xeris Pharmaceuticals, Inc. | Chicago, IL | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Marinus Pharmaceuticals, Inc., doing business as Marinus Pharmaceuticals, is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, a drug offering a new mechanism of action with demonstrated safety and convenient dosing for patients affected by epilepsy and CNS disorders. The company is registered as a for-profit corporate entity in SAM.gov to receive federal contract awards.
Marinus Pharmaceuticals has been awarded a significant cost-sharing contract valued at approximately $33.7 million from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. This six-year contract supports the development of the intravenous drug ganaxolone, which could aid in the treatment of seizure disorders and has implications for emergency response. The company has not been designated for any set-asides on this prime contract award. Additionally, Marinus Pharmaceuticals does not currently hold any sub-grant awards from the federal government.
Marinus Pharmaceuticals holds two Federal Supply Schedule contracts awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 under Schedule 65 IB for drugs, pharmaceuticals, and hematology related products. The first is a multiple-award contract with a potential value of $3.2 million and a period of performance through November 2028. This contract facilitates delivery of pharmaceutical products, including Marinus Pharmaceuticals' patented drug ganaxolone for the treatment of epilepsy, depression, and post-traumatic stress disorder, to various VA medical centers nationwide. The second contract is an interim agreement under the same schedule for a shorter period with a lower potential value of $25,000. These contracts aim to streamline procurement of specialized medications for veterans within the VA healthcare system and leverage competitive pricing through a multiple-award contract mechanism.
SBA capabilities narrative
Marinus is dedicated to improving treatment outcomes for patients with rare epilepsies and seizure disorders. Our lead drug candidate is designed to exhibit anti-epileptic activity by virtue of its GABAA receptor modulating properties and is being developed in intravenous (IV) and oral formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
Quick answers
Is Immedica Pharma US Inc. registered in SAM.gov?
Yes. Immedica Pharma US Inc.'s SAM.gov registration is active through March 13, 2027.
Which contract vehicles does Immedica Pharma US Inc. hold?
Immedica Pharma US Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Immedica Pharma US Inc.'s most recent federal award?
Immedica Pharma US Inc.'s most recent federal contract award is Development of intravenous drug ganaxolone (75A50120C00159), from Office of the Assistant Secretary for Preparedness and Response, on September 8, 2020.
On GovTribe
See Immedica Pharma US Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors